Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit

Journal of Clinical Microbiology

Volumn 46, Issue 7, 2008, Pages 2345-2352

  Chua, Thea ^a   Moore, Carol L ^a   Perri, Mary B ^a   Donabedian, Susan M ^a   Masch, William ^b   Vager, Dora ^a   Davis, Susan L ^a,c   Lulek, Kaitlin ^a,c   Zimnicki, Benjamin ^a,c   Zervos, Marcus J ^a,d  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DAPTOMYCIN; PANTON VALENTINE LEUKOCIDIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; VIRULENCE FACTOR;

ADULT; AFRICAN AMERICAN; AGED; AGR GENE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOMATION; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CATHETER INFECTION; CENTRAL VENOUS CATHETER; COMMUNITY; DILUTION; EPSILOMETER TEST; FEMALE; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEC GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SKIN INFECTION; UNITED STATES; URBAN AREA; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; WOUND INFECTION; ADOLESCENT; ANTIBIOTIC RESISTANCE; BACTERIUM IDENTIFICATION; CLASSIFICATION; CLUSTER ANALYSIS; COMMUNICABLE DISEASE; CROSS INFECTION; DNA FINGERPRINTING; DRUG EFFECT; EPIDEMIOLOGY; GENETICS; GENOTYPE; GEOGRAPHY; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; URBAN POPULATION;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; CLUSTER ANALYSIS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DNA FINGERPRINTING; DNA, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; EPIDEMIOLOGY, MOLECULAR; FEMALE; GENOTYPE; GEOGRAPHY; HUMANS; MALE; METHICILLIN RESISTANCE; MICHIGAN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; URBAN POPULATION; VANCOMYCIN RESISTANCE; VIRULENCE FACTORS;

EID: 49049114552     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00154-08     Document Type: Article

References (53)

1. Boyce, J. M., R. L. White, and E. Y. Spruill. 1983. Impact of methicillinresistant Staphylococcus aureus on the incidence of nosocomial staphylococcal infections. J. Infect. Dis. 148:763.
2. Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morb. Mortal. Wkly. Rep. 46:765-766.
3. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin - United States, 2002. Morb. Mortal. Wkly. Rep. 51:565-567.
4. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing: 15th informational supplement. Document M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Cosgrove, S. E., Y. Qi, K. S. Kaye, S. Harbarth, A. W. Karchmer, and Y. Carmeli. 2005. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 26:166-174.
6. Cosgrove, S. E., G. Sakoulas, E. N. Perencevich, M. J. Schwaber, A. W. Karchmer, and Y. Carmeli. 2003. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 36:53-59.
7. Crum, N. F., R. U. Lee, S. A. Thornton, O. C. Stine, M. R. Wallace, C. Barrozo, A. Keefer-Norris, S. Judd, and K. L. Russell. 2006. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am. J. Med. 119:943-951.
8. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.
9. Davis, S. L., M. B. Perri, S. M. Donabedian, C. Manierski, A. Singh, D. Vager, N. Z. Haque, K. Speirs, R. R. Muder, B. Robinson-Dunn, M. K. Hayden, and M. J. Zervos. 2007. Epidemiology and outcomes of communityassociated methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol. 45:1705-1711.
10. Fowler, V. G., Jr., J. M. Miro, B. Hoen, C. H. Cabell, E. Abrutyn, E. Rubinstein, G. R. Corey, D. Spelman, S. F. Bradley, B. Barsic, P. A. Pappas, K. J. Anstrom, D. Wray, C. Q. Fortes, I. Anguera, E. Athan, P. Jones, J. T. van der Meer, T. S. Elliott, D. P. Levine, A. S. Bayer, and ICE Investigators. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012-3021.
11. Gonzalez, B. E., A. M. Rueda, S. A. Shelburne III, D. M. Musher, R. J. Hamill, and K. G. Hulten. 2006. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect. Control Hosp. Epidemiol. 27:1051-1056.
12. Haque, N. Z., S. L. Davis, C. L. Manierski, D. Vager, S. M. Donabedian, M. B. Perri, R. Sabbagh, F. Cheema, and M. J. Zervos. 2007. Infective endocarditis caused by USA300 methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30:72-77.
13. Hidayat, L. K., D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144.
14. Horan, T. C., and R. P. Gaynes. 2004. Surveillance of nosocomial infections, p. 1672-1689. In C. G. Mayhall (ed.), Hospital epidemiology and infection control, 3rd ed. Lippincott Williams and Wilkins, Philadelphia, PA.
15. Johnson, J. K., T. Khoie, S. Shurland, K. Kreisel, O. C. Stine, and M. C. Roghmann. 2007. Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 clone. Emerg. Infect. Dis. 13:1195-1200.
16. Klein, E., D. L. Smith, and R. Laxminarayan. 2007. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis. 13:1840-1846.
17. Klevens, R. M., M. A. Morrison, S. K. Fridkin, A. Reingold, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, G. Fosheim, L. K. McDougal, F. C. Tenover, and Active Bacterial Core Surveillance of the Emerging Infections Program Network. 2006. Community-associated methicillin-resistant Staphylococcus aureus and healthcare risk factors. Emerg. Infect. Dis. 12:1991-1993.
18. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, S. K. Fridkin, and Active Bacterial Core Surveillance (ABCs) MRSA Investigators. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
19. Kuehnert, M. J., H. A. Hill, B. A. Kupronis, J. I. Tokars, S. L. Solomon, and D. B. Jernigan. 2005. Methicillin-resistant Staphylococcus aureus hospitalizations, United States. Emerg. Infect. Dis. 11:868-872.
20. Lina, G., Y. Piémont, F. Godail-Gamot, M. Bes, M. O. Peter, V. Gauduchon, F. Vandenesch, and J. Etienne. 1999. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 29:1128-1132.
21. Liu, C., and H. F. Chambers. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47:3040-3045.
22. Lodise, T. P., and P. S. McKinnon. 2005. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis. 52:113-122.
23. Maclayton, D. O., K. J. Suda, K. A. Coval, C. B. York, and K. W. Garey. 2006. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/ml and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin. Ther. 28:1208-1216.
24. McDougal, L. K., C. D. Steward, G. E. Killgore, J. M. Chaitram, S. K. McAllister, and F. C. Tenover. 2003. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120.
25. Moise, P. A., D. S. Smyth, N. El-Fawal, D. A. Robinson, P. N. Holden, A. Forrest, and G. Sakoulas. 2008. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 61:85-90.
26. Moise-Broder, P. A., G. Sakoulas, G. M. Eliopoulos, J. J. Schentag, A. Forrest, and R. C. Moellering, Jr. 2004. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38:1700-1705.
27. National Nosocomial Infections Surveillance System. 2004. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control. 32:470-485.
28. Okuma, K., K. Iwakawa, J. D. Turnidge, W. B. Grubb, J. M. Bell, F. G. O'Brien, G. W. Coombs, J. W. Pearman, F. C. Tenover, M. Kapi, C. Tiensasitorn, T. Ito, and K. Hiramatsu. 2002. Dissemination of new methicillinresistant Staphylococcus aureus clones in the community. J. Clin. Microbiol. 40:4289-4294.
29. Patel, J. B., L. A. Jevitt, J. Hageman, L. C. McDonald, and F. C. Tenover. 2006. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42:1652-1653.
30. Pfaller, M. A., R. N. Jones, G. V. Doern, and K. Kugler. 1998. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. 42:1762-1770.
31. Sakoulas, G., G. M. Eliopoulos, R. C. Moellering, Jr., R. P. Novick, L. Venkataraman, C. Wennersten, P. C. DeGirolami, M. J. Schwaber, and H. S. Gold. 2003. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J. Infect. Dis. 187:929-938.
32. Sakoulas, G., G. M. Eliopoulos, R. C. Moellering, Jr., C. Wennersten, L. Venkataraman, R. P. Novick, and H. S. Gold. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492-1502.
33. Sakoulas, G., P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, Jr., and G. M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
34. Sancak, B., S. Ercis, D. Menemenlioglu, S. Colakoglu, and G. Hasçelik. 2005. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J. Antimicrob. Chemother. 56:519-523.
35. Saravolatz, L. D., N. Markowitz, L. Arking, D. Pohlod, and E. Fisher. 1982. Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. Ann. Intern. Med. 96:11.
36. Seybold, U., E. V. Kourbatova, J. G. Johnson, S. J. Halvosa, Y. F. Wang, M. D. King, S. M. Ray, and H. M. Blumberg. 2006. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis. 42:647-656.
37. Shurland, S., M. Zhan, D. D. Bradham, and M. C. Roghmann. 2007. Comparison of mortality risk associated with bacteremia due to methicillinresistant and methicillin-susceptible Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 28:273-279.
38. Sievert, D., J. T. Rudrik, J. B. Patel, L. C. McDonald, M. J. Wilkins, and J. C. Hageman. 2008. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin. Infect. Dis. 46:668-674.
39. Singh, A., R. V. Goering, S. Simjee, S. L. Foley, and M. J. Zervos. 2006. Application of molecular techniques to the study of hospital infection. Clin. Microbiol. Rev. 19:512-530.
40. Soriano, A., F. Marco, J. A. Martínez, E. Pisos, M. Almela, V. P. Dimova, D. Alamo, M. Ortega, J. Lopez, and J. Mensa. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
41. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794.
42. Strommenger, B., C. Cuny, G. Werner, and W. Witte. 2004. Obvious lack of association between dynamics of epidemic methicillin-resistant Staphylococcus aureus in central Europe and agr specificity groups. Eur. J. Clin. Microbiol. Infect. Dis. 23:15-19.
43. Sung, J. M., and J. A. Lindsay. 2007. Staphylococcus aureus strains that are hypersusceptible to resistance gene transfer from enterococci. Antimicrob. Agents Chemother. 51:2189-2191.
44. Tallent, S. M., T. Bischoff, M. Climo, B. Ostrowsky, R. P. Wenzel, and M. B. Edmond. 2002. Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections. J. Clin. Microbiol. 40:2249-2250.
45. Tenover, F. C., L. K. McDougal, R. V. Goering, G. Killgore, S. J. Projan, J. B. Patel, and P. M. Dunman. 2006. Characterization of a strain of communityassociated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J. Clin. Microbiol. 44:108-118.
46. Tenover, F. C., and R. C. Moellering, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215.
47. Walsh, T. R., A. Bolmström, A. Qwärnström, P. Ho, M. Wootton, R. A. Howe, A. P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.
48. Wang, G., J. F. Hindler, K. W. Ward, and D. A. Bruckner. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886.
49. Weigel, L. M., R. M. Donlan, D. H. Shin, B. Jensen, N. C. Clark, L. K. McDougal, W. Zhu, K. A. Musser, J. Thompson, D. Kohlerschmidt, N. Dumas, R. J. Limberger, and J. B. Patel. 2007. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial bio-film. Antimicrob. Agents Chemother. 51:231-238.
50. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
51. Wootton, M., A. P. MacGowan, T. R. Walsh, and R. A. Howe. 2007. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 45:329-332.
52. Zhang, K., J. A. McClure, S. Elsayed, T. Louie, and J. M. Conly. 2005. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5026-5033.
53. Zhu, W., N. C. Clark, L. K. McDougal, J. Hageman, L. C. McDonald, and J. B. Patel. 2008. Vancomycin-resistant Staphylococcus aureus associated with Inc18-like vanA plasmids in Michigan. Antimicrob. Agents Chemother. 52:452-457.